
    
      The treatment arm will receive the starting dose of liraglutide of 0.6mg/d subcutaneously
      once daily, and the dose will be increased to 1.8mg/d in two weeks, and then continue to
      administrate this dose for 90 days. The control arm will not use liraglutide. Other types of
      GLP-1 analogues or degraded by dipeptidyl peptidase-IV (DPP-IV) inhibitors will be
      prohibited. Study visits will be performed at day 7, day 30±3 and at 90±7 day.
    
  